Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Open Orphan Plc ( (GB:HVO) ) just unveiled an update.
hVIVO plc reported a record performance in 2024, with revenues rising by 11.9% to £62.7 million and an EBITDA margin of approximately 26%. The company achieved these results through the successful execution of its growth strategy, which included the launch of the world’s largest human challenge trial unit and the expansion of its service offerings. The company’s diversification into new services such as standalone laboratory and field study services, along with the opening of new facilities, contributed to enhanced revenue and margins. The substantial cash reserves and strategic growth initiatives position hVIVO strongly for future revenue growth, targeting £100 million by 2028.
More about Open Orphan Plc
hVIVO plc is a rapidly expanding contract research organization (CRO) that specializes in early-stage drug development, particularly in testing vaccines and therapeutics for infectious and respiratory diseases through human challenge clinical trials. The company provides comprehensive early clinical development services to a broad client base, including some of the world’s largest biopharma companies. hVIVO boasts a unique portfolio of human challenge models and offers a range of additional services such as virology, immunology testing, and clinical trial site services.
YTD Price Performance: 2.93%
Average Trading Volume: 3,019,832
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £133.4M
For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.
